You are here

VRTX

$119.92

+1.11%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
May 19, 2017
- New Program Helps CF Families Pursue Higher Education - BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program. Each of the 40 scholarship recipients will be awarded $5,00...
May 18, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.m. ET. Management's remarks will be available live through Vertex's website at www.vrtx.com ...
May 17, 2017
- Precision medicine decision based on in vitro data and supported by more than five years of real-world clinical data that demonstrate KALYDECO's strong safety and efficacy profile for eligible patients - - Vertex working with FDA to obtain rapid approval for more than 600 additional people who h...
May 4, 2017
Third Annual CF "Circle of Care" Grants Connect CF Community Members Around the World to Share Their Ideas and Inspiration BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circl...
Apr 27, 2017
-First-quarter 2017 cystic fibrosis product revenues of $481 million; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million- ...
Apr 12, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1...
Mar 28, 2017
-Study in people who have two copies of the F508del mutation demonstrated a mean absolute improvement in ppFEV1 of 4.0 percentage points compared to placebo (p...
Mar 6, 2017
-Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF- -Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments- BOSTON--(BUSINESS WIRE)-- ...
Mar 2, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6th at 2:00 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com i...
Jan 25, 2017
-2016 total CF product revenues of $1.68 billion compared to $982 million in 2015; $980 million for ORKAMBI and $703 million for KALYDECO- -Fourth-quarter 2016 total CF product revenues of $454 million; $277 million for ORKAMBI and $177 million for KALYDECO- -Company reite...
Jan 11, 2017
-Merck KGaA, Darmstadt, Germany licenses two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs- -Vertex receives upfront payment of $230 million plus royalties on future sales- BOSTON--(BUSINESS WIRE)-- Ve...
Jan 8, 2017
-Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI pr...
Jan 4, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 12:30 p.m. ET (9:30 a.m. PT). The audio portion of management's remarks can be ...
Dec 19, 2016
LONDON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory Health Insurances (GKV-SV). ORKAMBI is the first medicine to ...
Nov 7, 2016
- Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI2.5) compared to placebo through 24 weeks of treatment - - ORKAMBI was well tolerated with safety data that were similar to data from previous Phase 3 open-label safety study - ...
Page:
...
Next Last